VERTANICAL

VERTANICAL is a biopharmaceutical company developing and distributing medicines for chronic pain. Its lead candidate, VER-01, is a cannabinoid-based drug for chronic low back pain, with additional programs listed for osteoarthritis and painful diabetic peripheral neuropathy.

The company describes its target customers as chronic pain patients and, through a physician portal, medical professionals. The website does not describe its revenue model beyond developing and distributing pharmaceuticals. The site lists clinical studies (including Phase 1 to 3 trials and a marketing authorisation application for VER-01 for chronic low back pain) and a pharmacovigilance reporting page.

The company is registered in Germany and its job postings are located in Gräfelfing near Munich. The careers page says prior pharmaceutical experience is not required for the open positions. It lists 18 open roles, mainly in clinical trials, quality assurance and regulatory affairs, and scientific marketing, with a range of director and manager levels.

Product: VER-01, a cannabinoid-based prescription drug candidate for chronic pain, currently in clinical development with a marketing authorisation application filed.